<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855164</url>
  </required_header>
  <id_info>
    <org_study_id>CLJN452A2202</org_study_id>
    <secondary_id>2015-005215-33</secondary_id>
    <nct_id>NCT02855164</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)</brief_title>
  <acronym>FLIGHT-FXR</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to assess the effects of different doses of tropifexor (LJN452)&#xD;
      with respect to safety, tolerability, and on markers of liver inflammation in patients with&#xD;
      NASH&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A In Part A, 77 subjects were randomized at baseline to receive tropifexor (10 μg, 30&#xD;
      μg, 60 μg or 90 μg) or placebo (Arms A, B, C, D and E) for 12 weeks. After ≥ 90% of the&#xD;
      subjects from Part A completed 8 weeks of treatment, the first interim analysis of all Part A&#xD;
      data was performed and the Data Monitoring Committee (DMC) recommended evaluation of 90 μg&#xD;
      tropifexor (safe andefficacious) in Part B. The treatment arms of Part A were completed&#xD;
      through Week 16 without adaptation.&#xD;
&#xD;
      Part B Randomization for Part B was started after the DMC recommendations on the dose to be&#xD;
      used in Part B were implemented by the sponsor. As planned in the study protocol, since the&#xD;
      first interim analysis selected one active dose (90 μg) to be tested in Part B, one of the&#xD;
      other originally planned active treatment arms (60 μg) was included with a smaller sample&#xD;
      size to confirm the earlier findings of this dose observed in Part A. Therefore, in Part B,&#xD;
      121 subjects, were randomized at baseline to receive tropifexor (90 μg and 60 μg) or placebo&#xD;
      (Arms F, G and H) for 12 weeks.&#xD;
&#xD;
      Part C was introduced as a result of the DMC recommendation to pursue doses &gt; 90 μg.&#xD;
      Randomization in Part C started once the Part B randomization was completed. In Part C, 152&#xD;
      subjects were randomized at baseline to receive 140 μg or 200 μg tropifexor or placebo (Arms&#xD;
      I, J and K) for 48 weeks.&#xD;
&#xD;
      One patient was treated at 2 sites but is still only one patient. 350 total enrollment, and&#xD;
      not 351.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Actual">April 6, 2020</completion_date>
  <primary_completion_date type="Actual">April 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This was a randomized, double-blind, placebo-controlled, multicenter, parallel-group, dose finding, 3-part (Parts A, B, and C), adaptive design study to assess the safety, tolerability, and efficacy of six doses of tropifexor as compared to placebo in subjects with NASH. Each study part had a screening period followed by a double-blind, randomized, treatment period, and a post-treatment follow-up period.&#xD;
This study was extended based on safety and efficacy results in Part A and available long-term toxicology coverage; Part C was added to explore 48 weeks of treatment at higher doses with paired biopsies in F2/3 NASH patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Nonalcoholic Steatohepatitis (NASH) Patients With Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure)</time_frame>
    <description>Number of Nonalcoholic steatohepatitis (NASH) patients with TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Transaminase Levels (ALT)</measure>
    <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure)</time_frame>
    <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage. High levels of ALT may indicate liver damage. Normal range for ALT is typically 10 to 45 U/L or so (varies a little by age and gender). Elevation of these values indicate more liver inflammation/damage.&#xD;
ALT elevation is not unexpected in this patient population&#xD;
Dose relationship of tropifexor (LJN452) on ALT marker of hepatic inflammation in NASH from baseline to week 12&#xD;
Summary statistics of change in ALT from baseline to EOT by treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Aspartate Transaminase (AST)</measure>
    <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure)</time_frame>
    <description>To determine the dose relationship of tropifexor (LJN452) on markers of hepatic inflammation (AST) in NASH from baseline to Week 12 The alanine aminotransferase (AST) test is a blood test that checks for liver damage. High levels of AST may indicate liver damage. Normal range for AST is typically 10 to 45 U/L or so (varies a little by age and gender). Elevation of these values indicate more liver inflammation/damage&#xD;
AST elevation is not unexpected in this patient population&#xD;
The aspartate aminotransferase (AST) test is a blood test that checks for liver damage. Higher levels indicate more possible liver damage&#xD;
Summary statistics of change in AST from baseline up to end of treatment (EOT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in % of Fat in the Liver Assessed Using Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure)</time_frame>
    <description>Repeated measures analysis: Relative change in percentage of fat in the liver assessed using MRI from baseline by visit up to EOT (Full analysis set)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight</measure>
    <time_frame>48 weeks</time_frame>
    <description>Repeated measures for LS mean change in weight after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Repeated measures for the LS mean change in BMI after 12 weeks of treatment. Body mass index (BMI) is a measure of body fat based on height and weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist to Hip (WTH) Ratio</measure>
    <time_frame>12 weeks</time_frame>
    <description>The LS mean change in waist to hip ratio after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biomarker FGF19</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>Dose-response relationship of tropifexor (LJN452) on FGF19 over time, a marker of FXR target engagement in the gut.&#xD;
ANCOVA: Ratio of FGF19 (pg/mL) post-dose to pre-dose at Week 6&#xD;
Value at 6 weeks minus value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biomarker C4</measure>
    <time_frame>Week 6, 4 hours post dose</time_frame>
    <description>Dose-response relationship of LJN452 on C4, a marker of hepatic target engagement at 4 hours post dose&#xD;
C4 (ng/mL): Summary statistics by treatment and visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Markers of Liver Fibrosis, Fibroscan</measure>
    <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12. For Part C, EoT was Week 48</time_frame>
    <description>Dose-response relationship of tropifexor (LJN452) on markers of liver fibrosis commonly available such as Fibroscan®&#xD;
Liver stiffness (kPa): Summary statistics by treatment and visit&#xD;
FibroScan is a specialized ultrasound machine for measuring fibrosis (scarring) in the liver&#xD;
Scores range from 0-4 with zero being no liver scarring and 4 being advanced liver scarring (cirrhosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Markers of Liver Fibrosis Panel (ELF) Score</measure>
    <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12. For Part C, EoT was Week 48</time_frame>
    <description>ANCOVA: LS Mean Change in Enhanced liver fibrosis panel (ELF) score from baseline by visit up to EOT.&#xD;
The total ELF score reference range calculated non-parametrically is 6.72 (90% CI 6.58-6.84) to 9.79 (90% CI 9.45-10.01); Journal of Hepatology 2013 vol. 59 j 236-242.&#xD;
Enhanced liver fibrosis Test (ELF) panel: the following was assessed: hyaluronic acid (HA), tissue inhibitor of metalloproteinases (TIMP-1), and amino-terminal pro-peptide of procollagen type III (PIIINP).&#xD;
The Enhanced Liver Fibrosis score is a linear combination of TIMP-1, PIIINP, and HA with the following formula: ELF score = 2.494+0.846 x ln(HA) + 0.735 x ln (PIIINP) + 0.391 x ln (TIMP-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Markers of Liver Fibrosis, Fibrotest (Parts A+B)</measure>
    <time_frame>End of Treatment (EoT):12 weeks</time_frame>
    <description>Fibrosis biomarker test, originally called Fibrotest®/ Fibrosure®, is combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT. The coefficient for the score is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e^-z).&#xD;
Calculated scores range from 0.00 (no fibrosis) to 1.00 (severe fibrosis or cirrhosis) (See Part C in separate outcomes that follows)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Markers of Liver Fibrosis, Fibrotest, (Part C)</measure>
    <time_frame>End of Treatment (EoT) was 48 weeks</time_frame>
    <description>Fibrosis biomarker test, originally called Fibrotest®/ Fibrosure®, is combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT. The coefficient for the score is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e^-z).&#xD;
Calculated scores range from 0.00 (no fibrosis) to 1.00 (severe fibrosis or cirrhosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Gamma-glutamyl Transferase (GGT)</measure>
    <time_frame>EoT for Parts A+B=12 weeks; EoT for Part C = 48 weeks</time_frame>
    <description>Summary statistics of change in GGT (IU/L) from baseline by visit up to EoT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Fasting Lipid Profile</measure>
    <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12. For Part C, EoT was Week 48</time_frame>
    <description>Repeated measures analysis: LS geometric mean ratio of fasting lipids to baseline by visit up to EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch Based on a Visual Analog Scale (VAS) Rating Scale</measure>
    <time_frame>EoT for Parts A+B=12 weeks; EoT for Part C = 48 weeks</time_frame>
    <description>Repeated measures analysis: Change in VAS for Itch from baseline by visit up to EoT&#xD;
VAS score 0 = no disease; and 9 is severely advanced disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Trough Concentration (Ctrough) of LJN452</measure>
    <time_frame>In Parts A and B, LJN452 Ctrough was measured on Study Days 7, 14, 28, 42, 56, and 84. In Part C LJN452 Ctrough was measured on Study Days 42, 84, 168, 280 and 336</time_frame>
    <description>Pre-dose Trough Concentration (Ctrough) of tropifexor (LJN452)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C2h (Steady-state Drug Levels 2 Hours Postdose) of LJN452</measure>
    <time_frame>Days 7 and 14 (10 and 30μg LJN452 C2h was not measured day 14)</time_frame>
    <description>Summary C2h of tropifexor (LJN452)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening of Steatohepatitis (Part C) - Total Score</measure>
    <time_frame>EoT (Week 48)</time_frame>
    <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (total score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening - FDA</measure>
    <time_frame>EoT (Week 48)</time_frame>
    <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (FDA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening - EMA</measure>
    <time_frame>EoT (Week 48)</time_frame>
    <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (EMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy-based Response at Week 48 Compared to Baseline: Difference Between Treatment Groups (Part C) - Resolution of Steatohepatitis (Diagnostic Category)</measure>
    <time_frame>EoT (Week 48)</time_frame>
    <description>Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy-based Response at Week 48 Compared to Baseline: Difference Between Treatment Groups (Part C) - Resolution of Steatohepatitis (FDA, EMA)</measure>
    <time_frame>EoT (Week 48)</time_frame>
    <description>Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Non-alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>LJN452 10 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452) Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LJN452 30 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452) Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LJN452 60 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifezor (LJN452) Parts A + B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LJN452 90 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452) Parts A + B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo A+ B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Parts A + B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LJN452 140 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452) Part C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LJN452 200 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452) Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Part C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropifexor (LJN452)</intervention_name>
    <description>Comparison of different doses of drug</description>
    <arm_group_label>LJN452 10 μg</arm_group_label>
    <arm_group_label>LJN452 140 μg</arm_group_label>
    <arm_group_label>LJN452 200 μg</arm_group_label>
    <arm_group_label>LJN452 30 μg</arm_group_label>
    <arm_group_label>LJN452 60 μg</arm_group_label>
    <arm_group_label>LJN452 90 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparator</description>
    <arm_group_label>Placebo A+ B</arm_group_label>
    <arm_group_label>Placebo C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male/female patients, 18 years or older&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  Part A and B patients : presence of NASH by histological evidence (liver biopsy&#xD;
             obtained 2 years or less prior to randomization) with fibrosis level of F1, F2 or F3&#xD;
             (fibrosis in the absence of cirrhosis) and no diagnosis of chronic liver disease and&#xD;
             elevated alanine aminotransferase (ALT) OR phenotypic diagnosis based on elevated ALT,&#xD;
             BMI and diagnosis of Type 2 diabetes mellitus (DM)&#xD;
&#xD;
          -  Part C patients: presence of NASH by histological evidence (liver biopsy obtained&#xD;
             during the Screening period or 6 months or less prior to randomization) with fibrosis&#xD;
             level of F2 or F3 and no diagnosis of chronic liver disease&#xD;
&#xD;
        And ( All Parts):&#xD;
&#xD;
          -  ALT ≥ 43 IU/L (males) or ≥ 28 IU/L (females)&#xD;
&#xD;
          -  Liver fat equal to or higher than 10% by MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous exposure to OCA&#xD;
&#xD;
          -  patients taking prohibited medications&#xD;
&#xD;
          -  patients taking the following medicines UNLESS on a stable dose (within 25% of&#xD;
             baseline dose) for at least 1 month before randomization: (for Part C patients, dose&#xD;
             must be stable for at least 1 month prior to biopsy through Screening : anti- diabetic&#xD;
             medications, insulin, beta-blockers, thiazide diuretics, fibrates, statins, niacin,&#xD;
             ezetimibe, vitamin E (if doses &gt; 200 IU/day; doses &gt; 800 IU/day are prohibited),&#xD;
             thyroid hormone, psychotropic medications, estrogen or estrogen containing birth&#xD;
             control&#xD;
&#xD;
          -  pregnant or nursing (lactating) women&#xD;
&#xD;
          -  current or history of significant alcohol consumption for a period of more than 3&#xD;
             consecutive months within 1 year prior to screening&#xD;
&#xD;
          -  uncontrolled diabetes mellitus&#xD;
&#xD;
          -  new use of GLP-1 agonists such as liraglutide, exenatide, lixisenatide, albiglutide or&#xD;
             dulaglutide within 3 months of screening&#xD;
&#xD;
          -  presence of cirrhosis&#xD;
&#xD;
          -  hepatic decompensation or severe liver impairment&#xD;
&#xD;
          -  previous diagnosis of other forms of chronic liver disease&#xD;
&#xD;
          -  patients with contraindications to MRI imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Alabama</state>
        <zip>35758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lonetree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208-2312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hatsukaichi city</city>
        <state>Hiroshima</state>
        <zip>738 8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saga-city</city>
        <state>Saga</state>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izumo-city</city>
        <state>Shimane</state>
        <zip>693 8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dongjak Gu</city>
        <state>Seoul</state>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaoshiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Keelung City</city>
        <zip>20401</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02913105?term=NASH+novartis&amp;rank=2</url>
    <description>A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <results_first_submitted>April 6, 2021</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2021</results_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LJN452</keyword>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>phase 2</keyword>
  <keyword>adaptive design</keyword>
  <keyword>randomized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02855164/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02855164/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total, 411 subjects were screened in Parts A and B of the study together. Of these, 198 subjects were deemed eligible to participate in the study and were subsequently randomized</recruitment_details>
      <pre_assignment_details>In Part A, 77 were randomized at baseline to receive tropifexor 10 μg (n=14), 30μg (n=16), 60 μg (n=16) or 90 μg (n=15) or placebo (n=16)&#xD;
In Part B, 121 were randomized at baseline to receive tropifexor 90 μg (n=70) and 60 μg (n=21) or placebo (n=30)&#xD;
780 were screened in Part C. Of these 152 met eligibility criteria and were randomized to receive tropifexor 140 μg (n=50) or 200 μg (n=51) or placebo (n=51)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LJN452 10 μg</title>
          <description>10 micrograms of Tropifexor (Part A)</description>
        </group>
        <group group_id="P2">
          <title>LJN452 30 μg</title>
          <description>30 micrograms of Tropifexor (Part A)</description>
        </group>
        <group group_id="P3">
          <title>LJN452 60 μg</title>
          <description>60 micrograms of Tropifexor (Parts A+B)</description>
        </group>
        <group group_id="P4">
          <title>LJN452 90 μg</title>
          <description>90 micrograms of Tropifexor (Parts A + B)</description>
        </group>
        <group group_id="P5">
          <title>Placebo A+B</title>
          <description>Placebo A+B</description>
        </group>
        <group group_id="P6">
          <title>LJN452 140 μg</title>
          <description>140 micrograms of Tropifexor (Part C)</description>
        </group>
        <group group_id="P7">
          <title>LJN452 200 μg</title>
          <description>200 micrograms of Tropifexor (Part C)</description>
        </group>
        <group group_id="P8">
          <title>Placebo C</title>
          <description>Placebo (Part C)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Parts A + B (Randomized Set)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="85"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="77"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C (Randomized Set)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="51"/>
                <participants group_id="P8" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="38"/>
                <participants group_id="P7" count="37"/>
                <participants group_id="P8" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) was all subjects to whom study treatment had been assigned. Following the intent-to-treat (ITT) principle, subjects were analyzed according to the treatment they have been assigned to at randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>LJN452 10 μg</title>
          <description>10 micrograms of Tropifexor (Part A)</description>
        </group>
        <group group_id="B2">
          <title>LJN452 30 μg</title>
          <description>30 micrograms of Tropifexor (Part A)</description>
        </group>
        <group group_id="B3">
          <title>LJN452 60 μg</title>
          <description>60 micrograms of Tropifexor (Parts A+B)</description>
        </group>
        <group group_id="B4">
          <title>LJN452 90 μg</title>
          <description>90 micrograms of Tropifexor (Parts A + B)</description>
        </group>
        <group group_id="B5">
          <title>Placebo A+B</title>
          <description>Placebo (Parts A+B)</description>
        </group>
        <group group_id="B6">
          <title>LJN452 140 μg</title>
          <description>140 micrograms of Tropifexor (Part C)</description>
        </group>
        <group group_id="B7">
          <title>LJN452 200 μg</title>
          <description>200 micrograms of Tropifexor (Part C)</description>
        </group>
        <group group_id="B8">
          <title>Placebo C</title>
          <description>Placebo (Part C)</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="85"/>
            <count group_id="B5" value="46"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="51"/>
            <count group_id="B8" value="51"/>
            <count group_id="B9" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Parts A + B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="46"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="50"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="51"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="41"/>
                    <measurement group_id="B8" value="43"/>
                    <measurement group_id="B9" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Full Analysis Set</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Parts A + B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="46"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="11.7"/>
                    <measurement group_id="B2" value="49" spread="14.4"/>
                    <measurement group_id="B3" value="50" spread="12.5"/>
                    <measurement group_id="B4" value="51" spread="13.4"/>
                    <measurement group_id="B5" value="51" spread="12.3"/>
                    <measurement group_id="B9" value="51" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="50"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="51"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="56" spread="11.41"/>
                    <measurement group_id="B7" value="55" spread="10.8"/>
                    <measurement group_id="B8" value="54" spread="11.0"/>
                    <measurement group_id="B9" value="55" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Sex of participant by treatment</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Parts A + B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="46"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="50"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="51"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="29"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian (Parts A + B)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="46"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B9" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black (Parts A + B)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="46"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian (Parts A + B)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="46"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B9" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander (Parts A + B)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="46"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Parts A + B)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="46"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown (Parts A+B)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="37"/>
                    <count group_id="B4" value="85"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian (Part C)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="50"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="51"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="38"/>
                    <measurement group_id="B9" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black (Part C)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="50"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="51"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian (Part C)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="50"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="51"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander (Part C)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="50"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="51"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Part C)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="50"/>
                    <count group_id="B7" value="51"/>
                    <count group_id="B8" value="51"/>
                    <count group_id="B9" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Nonalcoholic Steatohepatitis (NASH) Patients With Treatment Emergent Adverse Events (TEAE)</title>
        <description>Number of Nonalcoholic steatohepatitis (NASH) patients with TEAEs</description>
        <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure)</time_frame>
        <population>Safety analysis set (SAS) is all subjects who received at least one dose of drug and had at least one post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A+B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A+B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LNJ452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nonalcoholic Steatohepatitis (NASH) Patients With Treatment Emergent Adverse Events (TEAE)</title>
          <description>Number of Nonalcoholic steatohepatitis (NASH) patients with TEAEs</description>
          <population>Safety analysis set (SAS) is all subjects who received at least one dose of drug and had at least one post-baseline safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Transaminase Levels (ALT)</title>
        <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage. High levels of ALT may indicate liver damage. Normal range for ALT is typically 10 to 45 U/L or so (varies a little by age and gender). Elevation of these values indicate more liver inflammation/damage.&#xD;
ALT elevation is not unexpected in this patient population&#xD;
Dose relationship of tropifexor (LJN452) on ALT marker of hepatic inflammation in NASH from baseline to week 12&#xD;
Summary statistics of change in ALT from baseline to EOT by treatment</description>
        <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure)</time_frame>
        <population>Full analysis set (FAS): All subjects to whom study treatment had been assigned.&#xD;
Following the intent-to-treat (ITT) principle, subjects were analyzed according to the treatment they have been assigned to at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LNJ452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Transaminase Levels (ALT)</title>
          <description>The alanine aminotransferase (ALT) test is a blood test that checks for liver damage. High levels of ALT may indicate liver damage. Normal range for ALT is typically 10 to 45 U/L or so (varies a little by age and gender). Elevation of these values indicate more liver inflammation/damage.&#xD;
ALT elevation is not unexpected in this patient population&#xD;
Dose relationship of tropifexor (LJN452) on ALT marker of hepatic inflammation in NASH from baseline to week 12&#xD;
Summary statistics of change in ALT from baseline to EOT by treatment</description>
          <population>Full analysis set (FAS): All subjects to whom study treatment had been assigned.&#xD;
Following the intent-to-treat (ITT) principle, subjects were analyzed according to the treatment they have been assigned to at randomization.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="17.53"/>
                    <measurement group_id="O2" value="-12.0" spread="35.99"/>
                    <measurement group_id="O3" value="-17.3" spread="28.12"/>
                    <measurement group_id="O4" value="-15.4" spread="30.32"/>
                    <measurement group_id="O5" value="-8.1" spread="29.37"/>
                    <measurement group_id="O6" value="-27.0" spread="30.24"/>
                    <measurement group_id="O7" value="-28.7" spread="25.40"/>
                    <measurement group_id="O8" value="-11.7" spread="61.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>10 micrograms of Tropifexor vs placebo (Part A)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline up to EOT (Parts A + B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.362</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean change</param_type>
            <param_value>-15.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.2</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor vs placebo (Part A)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline up to EOT (Parts A + B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.729</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean change</param_type>
            <param_value>-10.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.8</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor vs placebo (Parts A + B)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline up to EOT (Parts A + B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.173</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Change</param_type>
            <param_value>-16.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.8</ci_lower_limit>
            <ci_upper_limit>-7.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>90 micrograms of Tropifexor vs placebo (Parts A + B)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline up to EOT (Parts A + B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.185</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Change</param_type>
            <param_value>-14.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.3</ci_lower_limit>
            <ci_upper_limit>-8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms of Tropifexor (Part C) vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline up to EOT (Part C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Change</param_type>
            <param_value>-31.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.9</ci_lower_limit>
            <ci_upper_limit>-16.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor vs placebo (Part C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline up to EOT (Part C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.030</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Change</param_type>
            <param_value>-32.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.6</ci_lower_limit>
            <ci_upper_limit>-14.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>10 micrograms of Tropifexor vs placebo (Parts A + B + C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline to Week 12 (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.456</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-13.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.3</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor vs placebo (Parts A + B + C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline to Week 12 (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.966</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-7.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.5</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor vs placebo (Parts A + B + C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline to Week 12 (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.275</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-13.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.4</ci_lower_limit>
            <ci_upper_limit>-5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>90 micrograms of Tropifexor vs placebo (Parts A + B + C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline to Week 12 (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.304</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-11.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.6</ci_lower_limit>
            <ci_upper_limit>-5.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms of Tropifexor vs placebo (Parts A + B + C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline up to EOT (Parts A + B) FAS</non_inferiority_desc>
            <p_value>0.057</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-17.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.5</ci_lower_limit>
            <ci_upper_limit>-9.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor vs placebo (Parts A + B + C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: ALT (U/L) change from baseline up to EOT (Parts A + B + C) FAS</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-23.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.5</ci_lower_limit>
            <ci_upper_limit>-15.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Aspartate Transaminase (AST)</title>
        <description>To determine the dose relationship of tropifexor (LJN452) on markers of hepatic inflammation (AST) in NASH from baseline to Week 12 The alanine aminotransferase (AST) test is a blood test that checks for liver damage. High levels of AST may indicate liver damage. Normal range for AST is typically 10 to 45 U/L or so (varies a little by age and gender). Elevation of these values indicate more liver inflammation/damage&#xD;
AST elevation is not unexpected in this patient population&#xD;
The aspartate aminotransferase (AST) test is a blood test that checks for liver damage. Higher levels indicate more possible liver damage&#xD;
Summary statistics of change in AST from baseline up to end of treatment (EOT)</description>
        <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure)</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aspartate Transaminase (AST)</title>
          <description>To determine the dose relationship of tropifexor (LJN452) on markers of hepatic inflammation (AST) in NASH from baseline to Week 12 The alanine aminotransferase (AST) test is a blood test that checks for liver damage. High levels of AST may indicate liver damage. Normal range for AST is typically 10 to 45 U/L or so (varies a little by age and gender). Elevation of these values indicate more liver inflammation/damage&#xD;
AST elevation is not unexpected in this patient population&#xD;
The aspartate aminotransferase (AST) test is a blood test that checks for liver damage. Higher levels indicate more possible liver damage&#xD;
Summary statistics of change in AST from baseline up to end of treatment (EOT)</description>
          <population>Full Analysis Set (FAS)</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="12.09"/>
                    <measurement group_id="O2" value="-2.1" spread="29.62"/>
                    <measurement group_id="O3" value="-10.2" spread="25.03"/>
                    <measurement group_id="O4" value="-2.5" spread="24.60"/>
                    <measurement group_id="O5" value="-7.1" spread="23.85"/>
                    <measurement group_id="O6" value="-16.7" spread="23.36"/>
                    <measurement group_id="O7" value="-13.3" spread="20.14"/>
                    <measurement group_id="O8" value="-13.1" spread="29.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>10 micrograms of Tropifexor vs placebo (Part A)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Full analysis set)</non_inferiority_desc>
            <p_value>0.722</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-9.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.9</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor vs placebo (Part A)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Full analysis set)</non_inferiority_desc>
            <p_value>0.468</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor vs placebo (Parts A+B)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Parts A+B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.774</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-8.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.7</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>90 micrograms of Tropifexor vs placebo (Parts A+B)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Parts A+B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.136</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms of Tropifexor vs placebo (Part C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Part C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.145</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-16.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.9</ci_lower_limit>
            <ci_upper_limit>-8.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor vs placebo (Part C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Part C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.236</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-15.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.2</ci_lower_limit>
            <ci_upper_limit>-6.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>10 micrograms of Tropifexor vs placebo (Parts A+B+ C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.788</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-7.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.7</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor vs placebo (Parts A+B+ C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.413</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor vs placebo (Parts A+B+ C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.833</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-6.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>90 micrograms of Tropifexor vs placebo (Parts A+B+ C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.068</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms of Tropifexor vs placebo (Parts A+B+ C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.269</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor vs placebo (Parts A+B+ C)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: AST (U/L) change from baseline up to EOT (Parts A+B+C) Full analysis set (FAS)</non_inferiority_desc>
            <p_value>0.777</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-3.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in % of Fat in the Liver Assessed Using Magnetic Resonance Imaging (MRI)</title>
        <description>Repeated measures analysis: Relative change in percentage of fat in the liver assessed using MRI from baseline by visit up to EOT (Full analysis set)</description>
        <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in % of Fat in the Liver Assessed Using Magnetic Resonance Imaging (MRI)</title>
          <description>Repeated measures analysis: Relative change in percentage of fat in the liver assessed using MRI from baseline by visit up to EOT (Full analysis set)</description>
          <population>FAS</population>
          <units>percentage of fat in the liver</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.48" spread="6.174"/>
                    <measurement group_id="O2" value="-14.07" spread="5.661"/>
                    <measurement group_id="O3" value="-15.04" spread="3.754"/>
                    <measurement group_id="O4" value="-12.34" spread="2.482"/>
                    <measurement group_id="O5" value="-6.19" spread="3.381"/>
                    <measurement group_id="O6" value="-31.25" spread="5.228"/>
                    <measurement group_id="O7" value="-39.54" spread="4.968"/>
                    <measurement group_id="O8" value="-3.58" spread="4.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>10 microgramsof Tropifexor - Change in percentage of fat in the liver Part A</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12</non_inferiority_desc>
            <p_value>0.853</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-7.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.174</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.66</ci_lower_limit>
            <ci_upper_limit>4.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor - Change in percentage of fat in the liver Part A</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12</non_inferiority_desc>
            <p_value>0.232</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-14.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.661</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.24</ci_lower_limit>
            <ci_upper_limit>-2.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor - Change in percentage of fat in the liver Parts A+B</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12</non_inferiority_desc>
            <p_value>0.077</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-15.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.754</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.45</ci_lower_limit>
            <ci_upper_limit>-7.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>90 micrograms of Tropifexor - Change in percentage of fat in the liver Parts A+B</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline</non_inferiority_desc>
            <p_value>0.141</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-12.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.482</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.23</ci_lower_limit>
            <ci_upper_limit>-7.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms of Tropifexor - Change in percentage of fat in the liver Part C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-31.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.228</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.58</ci_lower_limit>
            <ci_upper_limit>-20.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor - Change in percentage of fat in the liver Part C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12 (Parts A+B+C)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-39.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.968</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.37</ci_lower_limit>
            <ci_upper_limit>-29.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>10 micrograms of Tropifexor - Change in percentage of fat in the liver Parts A+B+C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12 (Parts A+B+C)</non_inferiority_desc>
            <p_value>0.872</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-8.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.650</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.06</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor - Change in percentage of fat in the liver Parts A+B+C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12 (Parts A+B+C)</non_inferiority_desc>
            <p_value>0.465</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-14.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.198</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.36</ci_lower_limit>
            <ci_upper_limit>-3.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor - Change in percentage of fat in the liver Parts A+B+C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12 (Parts A+B+C)</non_inferiority_desc>
            <p_value>0.228</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-15.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.75</ci_lower_limit>
            <ci_upper_limit>-8.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>90 micrograms - Change in percentage of fat in the liver Parts A+B+C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12 (Parts A+B+C)</non_inferiority_desc>
            <p_value>0.370</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-12.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.717</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.04</ci_lower_limit>
            <ci_upper_limit>-8.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms - Change in percentage of fat in the liver Parts A+B+C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12 (Parts A+B+C)</non_inferiority_desc>
            <p_value>0.029</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-18.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.517</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.51</ci_lower_limit>
            <ci_upper_limit>-12.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor - Change in percentage of fat in the liver Parts A+B+C</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANCOVA: Relative change in percentage of fat in the liver from baseline to Week 12 (Parts A+B+C)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean change</param_type>
            <param_value>-34.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.482</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.13</ci_lower_limit>
            <ci_upper_limit>-28.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight</title>
        <description>Repeated measures for LS mean change in weight after 12 weeks of treatment</description>
        <time_frame>48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A) vs placebo</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight</title>
          <description>Repeated measures for LS mean change in weight after 12 weeks of treatment</description>
          <population>FAS</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="0.608"/>
                    <measurement group_id="O2" value="-0.78" spread="0.567"/>
                    <measurement group_id="O3" value="-1.05" spread="0.377"/>
                    <measurement group_id="O4" value="-1.15" spread="0.253"/>
                    <measurement group_id="O5" value="0.00" spread="0.338"/>
                    <measurement group_id="O6" value="-5.10" spread="0.988"/>
                    <measurement group_id="O7" value="-5.89" spread="1.002"/>
                    <measurement group_id="O8" value="-2.48" spread="0.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>10 micrograms of Tropifexor (Part A) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in weight from baseline to EOT (Parts A + B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.010</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-1.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.608</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.99</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor (Part A) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in weight from baseline to EOT (Parts A + B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.237</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.567</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.90</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor (Parts A + B) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in weight from baseline to EOT (Parts A + B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.037</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.377</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>90 micrograms of Tropifexor (Parts A + B) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in weight from baseline to EOT (Parts A + B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.007</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-1.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.253</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.65</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms of Tropifexor (Part C) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in weight from baseline to EOT (Parts C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.053</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-5.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.988</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.05</ci_lower_limit>
            <ci_upper_limit>-3.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor (Part C) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in weight from baseline to EOT (Parts C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.013</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-5.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.002</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.87</ci_lower_limit>
            <ci_upper_limit>-3.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index (BMI)</title>
        <description>Repeated measures for the LS mean change in BMI after 12 weeks of treatment. Body mass index (BMI) is a measure of body fat based on height and weight</description>
        <time_frame>12 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index (BMI)</title>
          <description>Repeated measures for the LS mean change in BMI after 12 weeks of treatment. Body mass index (BMI) is a measure of body fat based on height and weight</description>
          <population>FAS</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.208"/>
                    <measurement group_id="O2" value="-0.29" spread="0.194"/>
                    <measurement group_id="O3" value="-0.35" spread="0.129"/>
                    <measurement group_id="O4" value="-0.42" spread="0.087"/>
                    <measurement group_id="O5" value="0.02" spread="0.116"/>
                    <measurement group_id="O6" value="-1.88" spread="0.322"/>
                    <measurement group_id="O7" value="-2.11" spread="0.327"/>
                    <measurement group_id="O8" value="-0.80" spread="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>10 micrograms of Tropifexor (Part A) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in BMI from baseline to EOT (Full analysis set)</non_inferiority_desc>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.208</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor (Part A) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in BMI from baseline to EOT (Full analysis set)</non_inferiority_desc>
            <p_value>0.177</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.194</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor (Parts A + B) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in BMI from baseline to EOT (Parts C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.032</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.129</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>90 micrograms of Tropifexor (Parts A + B) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in BMI from baseline to EOT (Full analysis set)</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.087</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms of Tropifexor (Part C) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in BMI from baseline to EOT (Full analysis set)</non_inferiority_desc>
            <p_value>0.015</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-1.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.322</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.51</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor (Part C) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in BMI from baseline to EOT (Parts C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-2.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.327</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.75</ci_lower_limit>
            <ci_upper_limit>-1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist to Hip (WTH) Ratio</title>
        <description>The LS mean change in waist to hip ratio after 12 weeks of treatment</description>
        <time_frame>12 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist to Hip (WTH) Ratio</title>
          <description>The LS mean change in waist to hip ratio after 12 weeks of treatment</description>
          <population>FAS</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="49"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.009"/>
                    <measurement group_id="O2" value="0.00" spread="0.008"/>
                    <measurement group_id="O3" value="-0.01" spread="0.005"/>
                    <measurement group_id="O4" value="0.00" spread="0.004"/>
                    <measurement group_id="O5" value="0.00" spread="0.005"/>
                    <measurement group_id="O6" value="0.00" spread="0.008"/>
                    <measurement group_id="O7" value="-0.01" spread="0.007"/>
                    <measurement group_id="O8" value="-0.02" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>10 micrograms of Tropifexor (Part A) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in WTH ratio from baseline to EOT (Parts A+B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.530</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.009</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>30 micrograms of Tropifexor (Part A) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in WTH ratio from baseline to EOT (Parts A+B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.857</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.008</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>60 micrograms of Tropifexor (Part A) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in WTH ratio from baseline to EOT (Parts A+B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.262</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.005</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>90 micrograms of Tropifexor (Parts A + B) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in WTH ratio from baseline to EOT (Parts A+B) (Full analysis set)</non_inferiority_desc>
            <p_value>0.323</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.004</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>140 micrograms of Tropifexor (Part C) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in WTH ratio from baseline to EOT (Part C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.100</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.008</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>200 micrograms of Tropifexor (Part C) vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated measures analysis: Change in WTH ratio from baseline to EOT (Part C) (Full analysis set)</non_inferiority_desc>
            <p_value>0.693</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean change</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.007</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Biomarker FGF19</title>
        <description>Dose-response relationship of tropifexor (LJN452) on FGF19 over time, a marker of FXR target engagement in the gut.&#xD;
ANCOVA: Ratio of FGF19 (pg/mL) post-dose to pre-dose at Week 6&#xD;
Value at 6 weeks minus value at baseline</description>
        <time_frame>baseline, week 6</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Biomarker FGF19</title>
          <description>Dose-response relationship of tropifexor (LJN452) on FGF19 over time, a marker of FXR target engagement in the gut.&#xD;
ANCOVA: Ratio of FGF19 (pg/mL) post-dose to pre-dose at Week 6&#xD;
Value at 6 weeks minus value at baseline</description>
          <population>FAS</population>
          <units>pg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="0.93" upper_limit="2.26"/>
                    <measurement group_id="O2" value="1.53" lower_limit="1.00" upper_limit="2.35"/>
                    <measurement group_id="O3" value="3.82" lower_limit="2.88" upper_limit="5.09"/>
                    <measurement group_id="O4" value="5.78" lower_limit="4.78" upper_limit="6.98"/>
                    <measurement group_id="O5" value="1.33" lower_limit="1.03" upper_limit="1.73"/>
                    <measurement group_id="O6" value="1.97" lower_limit="1.48" upper_limit="2.62"/>
                    <measurement group_id="O7" value="2.23" lower_limit="1.65" upper_limit="3.01"/>
                    <measurement group_id="O8" value="1.22" lower_limit="0.92" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Biomarker C4</title>
        <description>Dose-response relationship of LJN452 on C4, a marker of hepatic target engagement at 4 hours post dose&#xD;
C4 (ng/mL): Summary statistics by treatment and visit</description>
        <time_frame>Week 6, 4 hours post dose</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Biomarker C4</title>
          <description>Dose-response relationship of LJN452 on C4, a marker of hepatic target engagement at 4 hours post dose&#xD;
C4 (ng/mL): Summary statistics by treatment and visit</description>
          <population>FAS</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.82" spread="25.765"/>
                    <measurement group_id="O2" value="32.75" spread="23.360"/>
                    <measurement group_id="O3" value="28.38" spread="13.394"/>
                    <measurement group_id="O4" value="40.19" spread="31.356"/>
                    <measurement group_id="O5" value="47.70" spread="25.524"/>
                    <measurement group_id="O6" value="14.97" spread="20.232"/>
                    <measurement group_id="O7" value="8.54" spread="9.583"/>
                    <measurement group_id="O8" value="38.40" spread="24.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Markers of Liver Fibrosis, Fibroscan</title>
        <description>Dose-response relationship of tropifexor (LJN452) on markers of liver fibrosis commonly available such as Fibroscan®&#xD;
Liver stiffness (kPa): Summary statistics by treatment and visit&#xD;
FibroScan is a specialized ultrasound machine for measuring fibrosis (scarring) in the liver&#xD;
Scores range from 0-4 with zero being no liver scarring and 4 being advanced liver scarring (cirrhosis)</description>
        <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12. For Part C, EoT was Week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo (Part C)</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Markers of Liver Fibrosis, Fibroscan</title>
          <description>Dose-response relationship of tropifexor (LJN452) on markers of liver fibrosis commonly available such as Fibroscan®&#xD;
Liver stiffness (kPa): Summary statistics by treatment and visit&#xD;
FibroScan is a specialized ultrasound machine for measuring fibrosis (scarring) in the liver&#xD;
Scores range from 0-4 with zero being no liver scarring and 4 being advanced liver scarring (cirrhosis)</description>
          <population>FAS</population>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.94" spread="5.314"/>
                    <measurement group_id="O2" value="10.40" spread="7.663"/>
                    <measurement group_id="O3" value="9.90" spread="4.095"/>
                    <measurement group_id="O4" value="9.00" spread="4.152"/>
                    <measurement group_id="O5" value="9.30" spread="4.676"/>
                    <measurement group_id="O6" value="11.29" spread="3.677"/>
                    <measurement group_id="O7" value="12.03" spread="4.804"/>
                    <measurement group_id="O8" value="11.26" spread="4.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Markers of Liver Fibrosis Panel (ELF) Score</title>
        <description>ANCOVA: LS Mean Change in Enhanced liver fibrosis panel (ELF) score from baseline by visit up to EOT.&#xD;
The total ELF score reference range calculated non-parametrically is 6.72 (90% CI 6.58-6.84) to 9.79 (90% CI 9.45-10.01); Journal of Hepatology 2013 vol. 59 j 236-242.&#xD;
Enhanced liver fibrosis Test (ELF) panel: the following was assessed: hyaluronic acid (HA), tissue inhibitor of metalloproteinases (TIMP-1), and amino-terminal pro-peptide of procollagen type III (PIIINP).&#xD;
The Enhanced Liver Fibrosis score is a linear combination of TIMP-1, PIIINP, and HA with the following formula: ELF score = 2.494+0.846 x ln(HA) + 0.735 x ln (PIIINP) + 0.391 x ln (TIMP-1).</description>
        <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12. For Part C, EoT was Week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C) vs placebo</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>(Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Markers of Liver Fibrosis Panel (ELF) Score</title>
          <description>ANCOVA: LS Mean Change in Enhanced liver fibrosis panel (ELF) score from baseline by visit up to EOT.&#xD;
The total ELF score reference range calculated non-parametrically is 6.72 (90% CI 6.58-6.84) to 9.79 (90% CI 9.45-10.01); Journal of Hepatology 2013 vol. 59 j 236-242.&#xD;
Enhanced liver fibrosis Test (ELF) panel: the following was assessed: hyaluronic acid (HA), tissue inhibitor of metalloproteinases (TIMP-1), and amino-terminal pro-peptide of procollagen type III (PIIINP).&#xD;
The Enhanced Liver Fibrosis score is a linear combination of TIMP-1, PIIINP, and HA with the following formula: ELF score = 2.494+0.846 x ln(HA) + 0.735 x ln (PIIINP) + 0.391 x ln (TIMP-1).</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.158"/>
                    <measurement group_id="O2" value="0.00" spread="0.146"/>
                    <measurement group_id="O3" value="-0.19" spread="0.097"/>
                    <measurement group_id="O4" value="0.20" spread="0.064"/>
                    <measurement group_id="O5" value="0.08" spread="0.087"/>
                    <measurement group_id="O6" value="-0.34" spread="0.132"/>
                    <measurement group_id="O7" value="-0.24" spread="0.122"/>
                    <measurement group_id="O8" value="-0.08" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Markers of Liver Fibrosis, Fibrotest (Parts A+B)</title>
        <description>Fibrosis biomarker test, originally called Fibrotest®/ Fibrosure®, is combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT. The coefficient for the score is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e^-z).&#xD;
Calculated scores range from 0.00 (no fibrosis) to 1.00 (severe fibrosis or cirrhosis) (See Part C in separate outcomes that follows)</description>
        <time_frame>End of Treatment (EoT):12 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo (A+B)</title>
            <description>Placebo (Parts A+B)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Markers of Liver Fibrosis, Fibrotest (Parts A+B)</title>
          <description>Fibrosis biomarker test, originally called Fibrotest®/ Fibrosure®, is combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT. The coefficient for the score is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e^-z).&#xD;
Calculated scores range from 0.00 (no fibrosis) to 1.00 (severe fibrosis or cirrhosis) (See Part C in separate outcomes that follows)</description>
          <population>FAS</population>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.284"/>
                    <measurement group_id="O2" value="-1.49" spread="0.852"/>
                    <measurement group_id="O3" value="-1.44" spread="1.080"/>
                    <measurement group_id="O4" value="-1.34" spread="1.222"/>
                    <measurement group_id="O5" value="-1.23" spread="1.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Markers of Liver Fibrosis, Fibrotest, (Part C)</title>
        <description>Fibrosis biomarker test, originally called Fibrotest®/ Fibrosure®, is combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT. The coefficient for the score is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e^-z).&#xD;
Calculated scores range from 0.00 (no fibrosis) to 1.00 (severe fibrosis or cirrhosis)</description>
        <time_frame>End of Treatment (EoT) was 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O3">
            <title>Placebo A+B</title>
            <description>Placebo A+B</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Markers of Liver Fibrosis, Fibrotest, (Part C)</title>
          <description>Fibrosis biomarker test, originally called Fibrotest®/ Fibrosure®, is combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT. The coefficient for the score is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e^-z).&#xD;
Calculated scores range from 0.00 (no fibrosis) to 1.00 (severe fibrosis or cirrhosis)</description>
          <population>FAS</population>
          <units>scores</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.131"/>
                    <measurement group_id="O2" value="-0.44" spread="0.135"/>
                    <measurement group_id="O3" value="-0.17" spread="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Gamma-glutamyl Transferase (GGT)</title>
        <description>Summary statistics of change in GGT (IU/L) from baseline by visit up to EoT</description>
        <time_frame>EoT for Parts A+B=12 weeks; EoT for Part C = 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Gamma-glutamyl Transferase (GGT)</title>
          <description>Summary statistics of change in GGT (IU/L) from baseline by visit up to EoT</description>
          <population>FAS</population>
          <units>IU/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="10.93"/>
                    <measurement group_id="O2" value="-29.9" spread="10.11"/>
                    <measurement group_id="O3" value="-34.2" spread="6.70"/>
                    <measurement group_id="O4" value="-45.7" spread="4.52"/>
                    <measurement group_id="O5" value="-5.0" spread="6.10"/>
                    <measurement group_id="O6" value="-35.2" spread="11.58"/>
                    <measurement group_id="O7" value="-29.9" spread="11.65"/>
                    <measurement group_id="O8" value="9.0" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Fasting Lipid Profile</title>
        <description>Repeated measures analysis: LS geometric mean ratio of fasting lipids to baseline by visit up to EOT</description>
        <time_frame>End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12. For Part C, EoT was Week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo (Parts A+B)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Fasting Lipid Profile</title>
          <description>Repeated measures analysis: LS geometric mean ratio of fasting lipids to baseline by visit up to EOT</description>
          <population>FAS</population>
          <units>mmol/L</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.949" lower_limit="0.888" upper_limit="1.014"/>
                    <measurement group_id="O2" value="1.003" lower_limit="0.945" upper_limit="1.065"/>
                    <measurement group_id="O3" value="1.029" lower_limit="0.989" upper_limit="1.070"/>
                    <measurement group_id="O4" value="1.029" lower_limit="1.002" upper_limit="1.057"/>
                    <measurement group_id="O5" value="0.956" lower_limit="0.923" upper_limit="0.991"/>
                    <measurement group_id="O6" value="1.032" lower_limit="0.975" upper_limit="1.093"/>
                    <measurement group_id="O7" value="1.071" lower_limit="1.012" upper_limit="1.133"/>
                    <measurement group_id="O8" value="0.977" lower_limit="0.928" upper_limit="1.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.920" lower_limit="0.766" upper_limit="1.091"/>
                    <measurement group_id="O2" value="0.919" lower_limit="0.789" upper_limit="1.071"/>
                    <measurement group_id="O3" value="0.960" lower_limit="0.868" upper_limit="1.062"/>
                    <measurement group_id="O4" value="1.048" lower_limit="0.978" upper_limit="1.123"/>
                    <measurement group_id="O5" value="0.991" lower_limit="0.904" upper_limit="1.085"/>
                    <measurement group_id="O6" value="1.070" lower_limit="0.934" upper_limit="1.226"/>
                    <measurement group_id="O7" value="1.068" lower_limit="0.936" upper_limit="1.219"/>
                    <measurement group_id="O8" value="0.883" lower_limit="0.782" upper_limit="0.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.923" lower_limit="0.834" upper_limit="1.020"/>
                    <measurement group_id="O2" value="1.044" lower_limit="0.953" upper_limit="1.142"/>
                    <measurement group_id="O3" value="1.092" lower_limit="1.029" upper_limit="1.159"/>
                    <measurement group_id="O4" value="1.104" lower_limit="1.060" upper_limit="1.150"/>
                    <measurement group_id="O5" value="0.943" lower_limit="0.893" upper_limit="0.995"/>
                    <measurement group_id="O6" value="1.056" lower_limit="0.972" upper_limit="1.147"/>
                    <measurement group_id="O7" value="1.200" lower_limit="1.106" upper_limit="1.302"/>
                    <measurement group_id="O8" value="0.973" lower_limit="0.903" upper_limit="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.019" lower_limit="0.946" upper_limit="1.096"/>
                    <measurement group_id="O2" value="1.001" lower_limit="0.937" upper_limit="1.069"/>
                    <measurement group_id="O3" value="0.961" lower_limit="0.920" upper_limit="1.004"/>
                    <measurement group_id="O4" value="0.897" lower_limit="0.870" upper_limit="0.924"/>
                    <measurement group_id="O5" value="0.959" lower_limit="0.922" upper_limit="0.998"/>
                    <measurement group_id="O6" value="0.855" lower_limit="0.800" upper_limit="0.913"/>
                    <measurement group_id="O7" value="0.824" lower_limit="0.772" upper_limit="0.879"/>
                    <measurement group_id="O8" value="1.033" lower_limit="0.973" upper_limit="1.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL/HDL Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.921" lower_limit="0.810" upper_limit="1.047"/>
                    <measurement group_id="O2" value="1.058" lower_limit="0.942" upper_limit="1.188"/>
                    <measurement group_id="O3" value="1.139" lower_limit="1.055" upper_limit="1.229"/>
                    <measurement group_id="O4" value="1.227" lower_limit="1.165" upper_limit="1.293"/>
                    <measurement group_id="O5" value="0.980" lower_limit="0.915" upper_limit="1.051"/>
                    <measurement group_id="O6" value="1.252" lower_limit="1.128" upper_limit="1.390"/>
                    <measurement group_id="O7" value="1.478" lower_limit="1.332" upper_limit="1.639"/>
                    <measurement group_id="O8" value="0.947" lower_limit="0.862" upper_limit="1.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Glycerol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0563" lower_limit="0.8722" upper_limit="1.2793"/>
                    <measurement group_id="O2" value="0.9376" lower_limit="0.7859" upper_limit="1.1185"/>
                    <measurement group_id="O3" value="0.9128" lower_limit="0.8112" upper_limit="1.0272"/>
                    <measurement group_id="O4" value="0.9915" lower_limit="0.9151" upper_limit="1.0743"/>
                    <measurement group_id="O5" value="0.9604" lower_limit="0.8641" upper_limit="1.0674"/>
                    <measurement group_id="O6" value="1.1115" lower_limit="0.9721" upper_limit="1.2709"/>
                    <measurement group_id="O7" value="0.9808" lower_limit="0.8571" upper_limit="1.1223"/>
                    <measurement group_id="O8" value="0.9846" lower_limit="0.8722" upper_limit="1.11116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Fatty Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.082" lower_limit="0.897" upper_limit="1.305"/>
                    <measurement group_id="O2" value="0.864" lower_limit="0.726" upper_limit="1.028"/>
                    <measurement group_id="O3" value="0.929" lower_limit="0.827" upper_limit="1.043"/>
                    <measurement group_id="O4" value="0.947" lower_limit="0.874" upper_limit="1.025"/>
                    <measurement group_id="O5" value="0.936" lower_limit="0.844" upper_limit="1.038"/>
                    <measurement group_id="O6" value="1.072" lower_limit="0.951" upper_limit="1.208"/>
                    <measurement group_id="O7" value="0.887" lower_limit="0.785" upper_limit="1.002"/>
                    <measurement group_id="O8" value="0.977" lower_limit="0.928" upper_limit="1.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Itch Based on a Visual Analog Scale (VAS) Rating Scale</title>
        <description>Repeated measures analysis: Change in VAS for Itch from baseline by visit up to EoT&#xD;
VAS score 0 = no disease; and 9 is severely advanced disease</description>
        <time_frame>EoT for Parts A+B=12 weeks; EoT for Part C = 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Part A)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Part A) vs placebo</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B) vs placebo</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>Placebo A+B</title>
            <description>Placebo for parts A + B</description>
          </group>
          <group group_id="O6">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O7">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O8">
            <title>Placebo Part C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Itch Based on a Visual Analog Scale (VAS) Rating Scale</title>
          <description>Repeated measures analysis: Change in VAS for Itch from baseline by visit up to EoT&#xD;
VAS score 0 = no disease; and 9 is severely advanced disease</description>
          <population>FAS</population>
          <units>scores</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.48"/>
                    <measurement group_id="O2" value="0.2" spread="0.43"/>
                    <measurement group_id="O3" value="0.4" spread="0.28"/>
                    <measurement group_id="O4" value="0.1" spread="0.19"/>
                    <measurement group_id="O5" value="0.6" spread="0.27"/>
                    <measurement group_id="O6" value="0.6" spread="0.37"/>
                    <measurement group_id="O7" value="1.1" spread="0.35"/>
                    <measurement group_id="O8" value="0.3" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Trough Concentration (Ctrough) of LJN452</title>
        <description>Pre-dose Trough Concentration (Ctrough) of tropifexor (LJN452)</description>
        <time_frame>In Parts A and B, LJN452 Ctrough was measured on Study Days 7, 14, 28, 42, 56, and 84. In Part C LJN452 Ctrough was measured on Study Days 42, 84, 168, 280 and 336</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O5">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O6">
            <title>LJN452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Trough Concentration (Ctrough) of LJN452</title>
          <description>Pre-dose Trough Concentration (Ctrough) of tropifexor (LJN452)</description>
          <population>FAS</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Profile day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.142" spread="0.119"/>
                    <measurement group_id="O2" value="0.355" spread="0.194"/>
                    <measurement group_id="O3" value="0.638" spread="0.453"/>
                    <measurement group_id="O4" value="1.215" spread="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.216" spread="0.127"/>
                    <measurement group_id="O2" value="0.505" spread="0.328"/>
                    <measurement group_id="O3" value="0.626" spread="0.281"/>
                    <measurement group_id="O4" value="1.115" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.118" spread="0.087"/>
                    <measurement group_id="O2" value="0.411" spread="0.250"/>
                    <measurement group_id="O3" value="0.639" spread="0.265"/>
                    <measurement group_id="O4" value="1.027" spread="0.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.094"/>
                    <measurement group_id="O2" value="0.382" spread="0.150"/>
                    <measurement group_id="O3" value="0.647" spread="0.344"/>
                    <measurement group_id="O4" value="1.032" spread="0.661"/>
                    <measurement group_id="O5" value="2.821" spread="1.659"/>
                    <measurement group_id="O6" value="3.533" spread="2.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.168" spread="0.088"/>
                    <measurement group_id="O2" value="0.474" spread="0.273"/>
                    <measurement group_id="O3" value="0.637" spread="0.278"/>
                    <measurement group_id="O4" value="1.041" spread="0.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.118" spread="0.080"/>
                    <measurement group_id="O2" value="0.366" spread="0.147"/>
                    <measurement group_id="O3" value="0.530" spread="0.357"/>
                    <measurement group_id="O4" value="1.095" spread="0.653"/>
                    <measurement group_id="O5" value="1.685" spread="0.874"/>
                    <measurement group_id="O6" value="2.286" spread="1.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1.889" spread="1.340"/>
                    <measurement group_id="O6" value="2.146" spread="1.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 280</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="2.129" spread="1.257"/>
                    <measurement group_id="O6" value="1.990" spread="1.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 336</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1.444" spread="1.077"/>
                    <measurement group_id="O6" value="1.979" spread="1.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C2h (Steady-state Drug Levels 2 Hours Postdose) of LJN452</title>
        <description>Summary C2h of tropifexor (LJN452)</description>
        <time_frame>Days 7 and 14 (10 and 30μg LJN452 C2h was not measured day 14)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 10 μg</title>
            <description>10 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O2">
            <title>LJN452 30 μg</title>
            <description>30 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O3">
            <title>LJN452 60 μg</title>
            <description>60 micrograms of Tropifexor (Parts A + B)</description>
          </group>
          <group group_id="O4">
            <title>LJN452 90 μg</title>
            <description>90 micrograms of Tropifexor (Parts A + B)</description>
          </group>
        </group_list>
        <measure>
          <title>C2h (Steady-state Drug Levels 2 Hours Postdose) of LJN452</title>
          <description>Summary C2h of tropifexor (LJN452)</description>
          <population>FAS</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Profile day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.190" spread="0.143"/>
                    <measurement group_id="O2" value="0.702" spread="0.399"/>
                    <measurement group_id="O3" value="1.228" spread="0.598"/>
                    <measurement group_id="O4" value="2.193" spread="1.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Profile day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.344" spread="0.727"/>
                    <measurement group_id="O4" value="2.001" spread="1.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening of Steatohepatitis (Part C) - Total Score</title>
        <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (total score)</description>
        <time_frame>EoT (Week 48)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O2">
            <title>LNJ452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O3">
            <title>Placebo C</title>
            <description>Placebo (Part C)</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening of Steatohepatitis (Part C) - Total Score</title>
          <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (total score)</description>
          <population>Full analysis set (FAS)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (total score)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.214</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (total score)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8074</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.196</ci_lower_limit>
            <ci_upper_limit>0.251</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening - FDA</title>
        <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (FDA)</description>
        <time_frame>EoT (Week 48)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O2">
            <title>LNJ452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O3">
            <title>Placebo A+B</title>
            <description>Placebo A+B</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening - FDA</title>
          <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (FDA)</description>
          <population>Full analysis set (FAS)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (FDA)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8070</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.028</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.191</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (FDA)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6233</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.052</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.173</ci_lower_limit>
            <ci_upper_limit>0.273</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening - EMA</title>
        <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (EMA)</description>
        <time_frame>EoT (Week 48)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O2">
            <title>LNJ452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O3">
            <title>Placebo A+B</title>
            <description>Placebo A+B</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening - EMA</title>
          <description>Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (EMA)</description>
          <population>Full analysis set (FAS)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (EMA)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.214</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (EMA)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8074</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.196</ci_lower_limit>
            <ci_upper_limit>0.251</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy-based Response at Week 48 Compared to Baseline: Difference Between Treatment Groups (Part C) - Resolution of Steatohepatitis (Diagnostic Category)</title>
        <description>Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)</description>
        <time_frame>EoT (Week 48)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O2">
            <title>LNJ452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O3">
            <title>Placebo A+B</title>
            <description>Placebo A+B</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy-based Response at Week 48 Compared to Baseline: Difference Between Treatment Groups (Part C) - Resolution of Steatohepatitis (Diagnostic Category)</title>
          <description>Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)</description>
          <population>Full analysis set (FAS)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7028</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.184</ci_lower_limit>
            <ci_upper_limit>0.252</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1713</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.129</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.098</ci_lower_limit>
            <ci_upper_limit>0.345</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy-based Response at Week 48 Compared to Baseline: Difference Between Treatment Groups (Part C) - Resolution of Steatohepatitis (FDA, EMA)</title>
        <description>Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)</description>
        <time_frame>EoT (Week 48)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>LJN452 140 μg</title>
            <description>140 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O2">
            <title>LNJ452 200 μg</title>
            <description>200 micrograms of Tropifexor (Part C)</description>
          </group>
          <group group_id="O3">
            <title>Placebo A+B</title>
            <description>Placebo A+B</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy-based Response at Week 48 Compared to Baseline: Difference Between Treatment Groups (Part C) - Resolution of Steatohepatitis (FDA, EMA)</title>
          <description>Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)</description>
          <population>Full analysis set (FAS)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Resolution of steatohepatitis (FDA, EMA) without worsening of fibrosis (NASH CRN staging)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2033</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.168</ci_lower_limit>
            <ci_upper_limit>0.278</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>To End of Treatment (EoT): For Parts A&amp;B, EoT was Week 12; For Part C, EoT was Week 48</time_frame>
      <desc>AEs are any untoward sign or symptom that occurred during the study treatment period&#xD;
350 patients were randomized. One patient was treated at 2 sites, so 351 enrolled may appearr in some places.</desc>
      <group_list>
        <group group_id="E1">
          <title>LJN452 10 μg</title>
          <description>LJN452 10 mcg (Part A)</description>
        </group>
        <group group_id="E2">
          <title>LJN452 30 μg</title>
          <description>30 micrograms of Tropifexor (Part A)</description>
        </group>
        <group group_id="E3">
          <title>LJN452 60 μg</title>
          <description>LJN452 60 mcg (Parts A+B)</description>
        </group>
        <group group_id="E4">
          <title>LJN452 90 μg</title>
          <description>90 micrograms of Tropifexor (Parts A + B)</description>
        </group>
        <group group_id="E5">
          <title>LJN452 140 μg</title>
          <description>LJN452 140 mcg (Part C)</description>
        </group>
        <group group_id="E6">
          <title>LJN452 200 μg</title>
          <description>LJN452 200 mcg (Part C)</description>
        </group>
        <group group_id="E7">
          <title>Placebo</title>
          <description>Placebo A+B+C</description>
        </group>
        <group group_id="E8">
          <title>Total</title>
          <description>Total</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial thickening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="233" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Viral sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="88" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No outputs were planned; and are not available for determining the effects of tropifexor on primary endpoints in the subset of patients who had historical biopsy data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

